Pfizer Inc.

NYSE:PFE  
39.58
+0.38 (+0.98%)
4:03:58 PM EDT: $39.50 -0.08 (-0.19%)
Products, Regulatory

Valneva plans to accelerate pediatric development of its Lyme vaccine candidate

Published: 12/02/2020 16:52 GMT
Pfizer Inc. (PFE) - Announces Acceleration of Pediatric Development for Lyme Disease Vaccine Candidate.
Phase 2 Study Vla15-221 Planned to Be Initiated in Q1 2021, Subject to Regulatory Approval.
First Clinical Study of Vla15 That Includes a Pediatric Population, Aged 5-17 Years.
Study Will Include Participants From 5-65 Years of Age and a Reduced Immunization Schedule (month 0-6 Compared to Month 0-2-6).
Study Will Trigger a Milestone Payment, Upon Dosing of First Subject, From Pfizer to Valneva of $10 Million.
Phase 3 Pivotal Efficacy Trial is Planned to Commence in 2022 Saint-herblain (france), December 2, 2020 - Valneva Se.
Vla15-221 is Planned As a Randomized, Observer-blind, Placebo-controlled Phase 2 Study.